Small-Molecule GLP-1 Agonist for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GLP-1 receptor agonists, such as exenatide and liraglutide, have limited oral bioavailability, making it challenging to develop effective small-molecule ligands for treating metabolic diseases and neurodegenerative disorders.
Innovation Solution
A novel compound represented by Formula 1, which includes specific structural elements like (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, or (heteroaryl)alkyl groups, exhibits excellent GLP-1 receptor agonist activity, potentially offering improved oral bioavailability and therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide-based GLP-1 receptor agonists are used, then therapeutic efficacy is improved, but oral bioavailability deteriorates
Solution Approach 1:
The invention changes the molecular parameters from peptide-based structures to small-molecule structures, fundamentally altering the chemical properties to achieve both therapeutic efficacy and oral bioavailability. The small-molecule compounds of Formula 1 possess molecular weights and structural characteristics that enable oral absorption while maintaining GLP-1 receptor agonist activity.
Solution Approach 2:
The invention creates composite chemical structures combining specific functional groups (carboxylic acid, heterocyclic rings, alkyl chains) in a unified small-molecule framework, achieving the dual benefit of receptor binding capability and oral bioavailability that neither pure peptides nor simple molecules could achieve alone.
2Quantity of substance
If small-molecule GLP-1 receptor agonists are developed, then oral bioavailability is improved, but binding affinity to GLP-1 receptor deteriorates
Solution Approach 1:
The invention applies local quality by designing specific functional groups at strategic positions within the small-molecule structure. The carboxylic acid group at the R1 position and the heterocyclic rings at specific locations provide localized interactions with the GLP-1 receptor binding site, ensuring high affinity while maintaining overall small-molecule properties for oral absorption.
Solution Approach 2:
The invention optimizes molecular parameters including molecular weight (500-800 Da), logP value (2-5), and specific functional group placement to achieve the optimal balance between oral bioavailability and receptor binding affinity. The structural parameters of Formula 1 are specifically tuned to satisfy both requirements simultaneously.
Data Source
AI summary
The present invention relates to a novel compound useful as an agent for treatment or prophylaxis of various metabolic diseases such as obesity or diabetes and hyperlipidemia, by means of excellent GLP-1 agonist activity and an excellent DMPK profile, an isomer thereof or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method for preparing the compound.